Advancing Next-Generation ADCs: Clinical Insights from the GlycoConnect® Platform & Expansion of Lonza’s toxSYN® Platform
12:30 pm - Tuesday 13th October 2026
- Discovering how Lonza’s GlycoConnect®, HydraSpace®, and toxSYN® technologies are shaping differentiated ADCs designed to enable improved therapeutic index
- Getting an inside look at a pipeline of 30+ GlycoConnect® ADCs, including clinical insights from advanced partner programs
- Exploring the future of targeted therapies dual payload toxSYN® classes to protein-protein conjugates with enhanced BBB transport
